pharmaphorum| News & views on pharma and biotech’s evolving future

Oncology

From promise to practice: What must happen next for genetic ...

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

News

UK Knowledge Quarter welcomes Boehringer Ingelheim AI accele...

Boehringer Ingelheim has announced expansion of its global Computational Innovation footprint with a new centre dedicated to AI & ML in the UK.

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

News

Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia

Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.

News

AZ is three for three with COPD hope tozorakimab

AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.

Featured Content

Oncology

From promise to practice: What must happen next for genetic ...

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

Sales & Marketing

Sponsored

Pushing through barriers to commercial launch success, with ...

In this sponsored pharmaphorum podcast, Amanjeet Singh Saluja, a Principal at Axtria, discusses the current state of affairs in launch success.

R&D

LSX2026: Endogenous tissue restoration in vascular disease –...

Paulo Neves, CMO of Xeltis, discusses transformative implants that enable the natural creation of living and long-lasting vessels.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Newsletters and Deep Dive
digital magazine

Latest News

News

UK Knowledge Quarter welcomes Boehringer Ingelheim AI accele...

Boehringer Ingelheim has announced expansion of its global Computational Innovation footprint with a new centre dedicated to AI & ML in the UK.

News

Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia

Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.

News

AZ is three for three with COPD hope tozorakimab

AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.

News

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

Views & Analysis

Oncology

From promise to practice: What must happen next for genetic ...

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

Digital

Changing Faces: Digital and supplier, March 2026

Digital health companies, clinical trial technology providers, and life sciences suppliers continued to invest in senior leadership in March.

R&D

The conflict in the Middle East is exposing dangerous prepar...

If the conflict persists, the risk of widespread medicine shortages becomes increasingly real.

Digital

AI in clinical trials for protocol ingestion

From static documents to strategic capability: The case for ...

Protocol documentation will become protocol ingestion – an approach that’s automated, consistent, and intelligent.

Deep Dive

R&D

The GLP-1 Reckoning

R&D

Redesigning obesity trials for a chronic disease era

R&D

GLP-1s: Five years that changed metabolic medicine

R&D

The trust gap: GLP-1s and the new information economy of obe...

White Papers & Webinar

R&D

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Sales & Marketing

Sponsored

What HCPs Say Pharma Gets Wrong About Survey Research

Most market researchers already know the standard rules: keep surveys concise, write clear questions, and reduce unnecessary respondent burden.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Podcasts & Video

R&D

LSX2026: Endogenous tissue restoration in vascular disease –...

Paulo Neves, CMO of Xeltis, discusses transformative implants that enable the natural creation of living and long-lasting vessels.

Sales & Marketing

Sponsored

Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey

Featured Content

Editor's Picks

Latest News

Views & Analysis

Deep Dive

White Papers & Webinar

Podcasts & Video

Partner Content